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ABSTRACT
The present study deals with effect of prenatal and neonatal administration of the synthetic pyridoindole derivative SMe1EC2 
(2-ethoxycarbonyl-8-methoxy-2,3,4,4a,5,9b-hexahydro-1H-pyrido-[4,3b] indolinium chloride) on postnatal and neurobehavioral 
development of the rat offspring. The substance tested was administered to pregnant rats orally in the doses 5, 50 and 250 mg/kg 
from day 15 of gestation to day 10 post partum (PP). From the day 4 PP, the postnatal development and neurobehavioral characteritics 
of offspring were evaluated. The following variables were observed: body weight, pinna detachment, incisor eruption, ear opening, 
eye opening, testes descent and vaginal opening, righting reflex, negative geotaxia, startle reflex, dynamic air righting and exploratory 
behavior in a new environment. No maternal death, abortion or dead fetuses occurred either in the control or SMe1EC2 groups. 
Dynamic righting reflex was delayed one day in the groups of animals treated via their mothers with 5 and 50 mg/kg SMe1EC2. The 
delay in the development of this reflex was only transient. On day 20 PP, all pups tested had a positive score of the reflex. Administra-
tion of SMe1EC2 did not reveal any significant changes in other variables of somatic growth and maturation, reflex and neuromotor 
development and exploratory behavior, either of young or adult animals of both genders, assessed by analysis of variance. 
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Hypoxia/ischemia associated with oxidative stress 
during prenatal and perinatal periods affects central 
nervous, cardiovascular, respiratory, gastrointestinal, 
hemopoetic and uropoetic systems, as well as the adre-
nal glands and the skin (Brucknerová, 2000). The most 
serious consequence is however injury of the developing 
brain manifested as hypoxic-ischemic encephalopathy, 
brain edema, bleeding to brain tissue, etc. (Dennery, 2007; 
Verklan, 2009). 
Hypoxia/ischemia brain injury in newborns can be 
therapeutically affected by means of substances with 
antioxidant and antiradical properties, such as vitamin C, 
α-tocopherol, trolox, lazaroids, selenoids, allopurinol, cal-
cium antagonists and calcium channel blockers (Penn et 
al., 1997; van Bel et al., 1998; Brucknerová, 2000; Cohen-
Kerem & Koren, 2003). Pyridoindole derivatives of the 
parental drug stobadine designed and synthesized at the 
Institute of Experimental Pharmacology and Toxicology, 
Slovak Academy of Sciences, Bratislava, Slovakia, repre-
sent prospective drugs in the therapy of hypoxia/isch-
emia in the developing organism. The most thoroughly 
studied pyridoindole derivative is 2-ethoxycarbonyl-
8-methoxy-2,3,4,4a,5,9b-hexahydro-1H-pyrido-[4,3b] 
Introduction
Chemical substances as well as biological and physical 
factors can adversely affect the developing organism. 
Abnormal embryo-fetal development becomes manifest 
at various levels, ranging from death of the embryo/
fetus, through serious congenital malformations to 
minor structural anomalies (Hood, 2006). Low doses of 
chemicals without any signs of maternal and embryo-fetal 
toxicity may interfere with developmental processes in the 
brain during prenatal as well as early postnatal periods. 
Functional maldevelopment of the brain, in turn, may 
result in neurological, behavioral, emotional and mental 
disorders, such as attention deficit-hyperactivity disorder, 
autism or schizophrenia (Cannon & Clarke, 2005; Kinney 
et al., 2008). 
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indolinium chloride, m.w. 312.79 Da, chemical purity > 
99% (SMe1EC2). The results of preclinical experimental 
studies showed significant antioxidant and neuroprotec-
tive effects of SMe1EC2 . This pyrodindole derivative has 
a very low toxicity, its LD50 is higher than 2400 mg/kg 
(Štolc et al., 2008). The results of a teratological study did 
not show any signs of maternal and embryofetal toxicity 
(Ujházy et al., 2008). As the parental drug stobadine 
showed protective effects on hypoxia induced injuries in 
the developing organism (Ujházy et al., 2004; 2006), it is 
possible to use the substance SMe1EC2 in the protection 
of embryos/fetuses and/or neonates against hypoxia/isch-
emia. However, every drug considered to be used during 
sensitive developmental stages must undergo preclinical 
safety assessment proced ures. I t is inevitable to have  
comprehensive knowledge on any possible adverse effects 
of the drug tested on the developing organism. 
The aim of this experimental study was to investigate 
the effect of prenatal and neonatal administration of 
SMe1EC2 on postnatal development of the rat offspring 
focused on neurobehavioral development. 
Material and methods
Developmental neurotoxicity study
In the present study we followed OECD Guideline No. 426 
(OECD, 2007). It is based on evaluation of the effect of the 
substance tested during sensitive developmental stages of 
the brain on the postnatal and neurobehavioral develop-
ment up to the adulthood. 
Animals
Virgin female Wistar/DV rats (n=69) aged 3–4 months, 
weight 200–220 g, and male rats (n=10), aged 3–4 months, 
weight 240–260  g obtained from the breeding station 
Dobrá Voda, Slovakia, were used. The animals were 
housed under standard experimental conditions (tem-
perature  21 ± 2 °C,  relative  humidity  55 ± 10%,  12/12 hr 
light-dark cycle, food and water provided ad libitum). 
After 7 days of acclimatization, the females were mated 
with males in the ratio 1 male : 3 females (presence of 
spermatozoa in vaginal smear indicated day 0 of gesta-
tion). Pregnant females were allowed to spontaneously 
deliver their pups (day 0 post partum, PP). On day 4 PP, 
the number of pups in each litter was reduced to 8 pups, 
4 males and 4 females. The pups were weaned on day 
2 1 PP . The experiment was performed in compliance 
with the Principles of Laboratory Animal Care issued by 
the Ethical Committee of the Institute of Experimental 
Pharmacology and Toxicology, Slovak Academy of 
Sciences. The experimental design was approved by the 
State Veterinary and Food Administration of the Slovak 
Republic.
Treatment 
The substance tested was administered to pregnant rats 
orally in the doses of 5, 50 and 250 mg/kg from day 15 
of gestation to day 10 PP. The substance was dissolved 
in saline at a constant dosage volume 0.5 ml/100 g body 
weight. Control animals received vehiculum at the same 
time schedule. 
Maternal observation
During administration of the substance tested to preg-
nat rats, the following signs of possible intoxication 
were observed: lacrimation, salivation, piloerection, 
exophthalmos, urination, defecation, mydriasis, ptosis, 
tremor, convulsions, abnormal movements and behavior, 
cachexia, dehydratation, hypotony or hypertony and fur 
changes. Further variables observed were body weight 
gains of pregnant females, duration of pregnancy, number 
of live and dead pups. 
Postnatal development of oﬀ  spring
Somatic growth and maturation
From day 4 PP we evaluated postnatal and neurobehav-
ioral development of offspring. We observed the following 
variables of somatic growth and maturation. Body weight 
(days 4, 7, 14 and 21 PP), pinna detachment (day 4 PP), 
incisor eruption (day 10 PP), ear opening (day 12 PP), eye 
opening (day 15 PP), testes descent (day 27 PP) and vaginal 
opening (day 35 PP).
Neuromotor and reflex development 
Within the neuromotor and reflex development assess-
ment, we observed righting reflex (on day 5 PP, the pup´s 
ability to turn over from supine position), negative geo-
taxia (8 PP, the pup´s ability to turn 180° on a 25° inclined 
placed head down), startle reflex (15 PP, the presence 
or absence of sensorimotor reaction – jerks to auditory 
stimulus expressed as a percentage of pups with negative 
reaction), dynamic air righting (15–20 PP, the pup´s abil-
ity to turn over in the air from supine position and fall 
down onto 4 limbs). 
Activity and emotional reactivity
Activity of the animals was recorded as exploratory 
behavior in a new environment (open field test). Young 
animals were tested by means of optoelectronic device 
ActiTrack (Panlab, Spain) on days 23–26 PP. The rat was 
placed in the center of the experimental glass box sized 
43 × 43 cm. Adult animals were tested in the experimental 
arena with a with dimensions 40 × 60 cm on days 90–93 
PP and analysed by videotracking software ANY-Maze 
(Stoelting Co., USA). Young as well as adult rats were 
tested on four consecutive days in 5 min sessions between 
8.00–12.00 A.M. After each individual test, the number of 
fecal boli left were recorded and the open field arena was 
cleaned with a mild detergent.
Statistics
Data were analyzed by means of analysis of variance. 
Data from repeated testings were analyzed by “repeated 
measures ANOVA”. Data from single tests were analyzed 
by one-way ANOVA. The values are presented as means 
± S.E.M. The confidence limit of p<0.05 was considered 
statistically significant. 49
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Results
Maternal toxicity
No maternal death, abortion or dead fetuses occurred 
either in the control or SMe1EC2 treated groups. The 
maternal body weight gains were not affected by the 
treatment with the substance tested (data not shown). 
There was only a significant effect of time on body weight 
gain, i.e. the body weight of mothers significantly changed 
during pregnancy and after delivery [F(4,144)=60.704; 
p<0.0001] (Figure 1).
Eﬀ  ects on oﬀ  spring
Body weight of offspring of either gender was not affected 
by SMe1EC2. In all experimental groups of both genders 
there was a significant gradual increase in body weight 
from day 4 to day 21 PP of experiment [F(3,219)=50.273; 
p<0.0001] (Figure 2 males, females data not shown). 
Individual variables of somatic growth and matura-
tion were not affected by the treatment with SMe1EC2. 
Similarly there was no significant effect of the substance 
tested on the variables of the neuromotor and reflex devel-
opment, except the dynamic air righting. During the test, 
there was a significant increase in the percentage of pups 
with positive score in both genders [Fmales(5,125)=144.92; 
p<0.0001, Ffemales(5,125)=134.73;  p<0.0001]. In males, 
there was a statistically significant effect of SMe1EC2 
t r e a t m e n t  o n  t h i s  v a r i a b l e  [ F ( 3 , 2 5 ) = 7 . 0 4 3 ;  p<0.01]. 
Fisher LSD post-hoc test revealed a significant decrease 
(p<0.001 ) in the percentage in the dose groups 5 and 
50 mg/kg SMe1EC2 on day 16 PP compared to controls 
(Figure 3). 
Analysis of variance did not reveal any significant 
changes in exploratory behavior of young or adult animals 
of either gender due to administration of SMe1EC2 during 
development (data not shown).
Discussion
Prenatal and perinatal periods are highly vulnerable to 
the action of various chemical substances and physi-
cal factors. It is inevitable for the healthy organism to 
maintain homeostasis and in the case of its perturbation 
to recover as soon as possible the former physiological 
status. Hypoxia/ischemia followed by production of reac-
tive oxygen species and oxidative stress is considered the 
most important factor for disturbation of homeostasis in 
the body (Hood, 2006; Dennery, 2007). Injuries induced 
by hypoxia/ischemia associated with oxidative stress in 
pregnancy and during parturition can be ameliorated 
by the use of natural products as well as synthetic drugs 
with antioxidant and antiradical properties. Experimental 
studies showed that treatment with antioxidants, such as 
vitamin C and E or butylated hydroxytoluene, can dimin-
ish embryofetal dysmorphogenesis due to gestational dia-
betes induced by hyperinsulinemia and hypoxia (Eriksson 
and Simán, 1996; Ponce et al., 2005;  Cederberg and 
Eriksson, 2005). Moreover, vitamin C in pregnancy may 
play a role in providing an antioxidant defense against 
reactive oxygen species affecting birth weight (Park et 
al., 2004). Melatonin seems to be involved in correcting 
the pathophysiology of complications during pregnancy, 
including those due to abortion, pre-eclampsia and fetal 
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Figure 1. Eff  ect of developmental administration of SMe1EC2 
on body weight gain in pregnant females. Doses: S1 – 5 mg/kg, 
S2 – 50 mg/kg, S3 – 250 mg/kg, G – gestation, PP – post partum. 
Figure 2. Eff  ect of developmental administration of SMe1EC2 
on body weight of male off  spring. Doses: S1 – 5 mg/kg, S2 – 
50 mg/kg, S3 – 250 mg/kg, PP – post partum. 
Figure 3. Eff  ect of developmental administration of SMe1EC2 
on dynamic righting refl  ex in male off  spring. Doses: S1 – 5 mg/
kg, S2 – 50 mg/kg, S3 – 250 mg/kg, PP – post partum. Eff  ect of 
treatment: F(3,25)=7.043, p<0.01, on day PP 16, S1 and S2 groups 
compared to control – Fisher LSD post-hoc, p<0.001.50
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brain damage (Tamura et al., 2008). Our previous experi-
mental studies showed that pretreatment of pregnant rats 
with stobadine prevented to a certain extent reproduc-
tive and fetal developmental alterations due to chronic 
intrauterine hypoxia induced by phenytoin (Ujházy et 
al., 2004). In the study of neonatal anoxia, stobadine 
reduced anoxia-induced hyperactivity in male offspring 
(Ujházy et al., 2006). Gáspárová et al. (2010) found that 
maternal treatment with SMe1EC2 improved resistance 
of the offspring hippocampus against transient ischemia 
in vitro. This was documented by improved recovery of 
electrically evoked neuronal response in reoxygenation. 
However, it is important to note that relatively high 
doses of the antioxidants are needed to normalize the 
development of offspring in experimental pathophysi-
ological conditions. Yet treatment whith such high doses 
may also have adverse effects on intact animals (Cedeberg 
and Eriksson, 2005). 
Concerning the synthetic pyridoindole derivative 
SMe1EC2 and its parental drug stobadine, series of 
preclinical relative safety studies were conducted in the 
past. In a teratological study on rats and mice, no signs of 
maternal and embryofetal toxicity were found (Ujházy et 
al., 1992; 1994). Similarly, stobadine in a long-term toxic-
ity and genotoxicity study (Gajdošíková et al., 1995) as 
well as in reproductive and behavioral studies (Balonová 
et al., 1991; Dubovický et al., 1999) did not exhibit any 
adverse effects. 
In our present preclinical study, we investigated the 
relative safety of SMe1EC2 after its administration to 
pregnant and lactating rats. The results showed that the 
substance tested did not cause any negative effects on 
somatic and neurobehavioral development of offspring 
until adulthood. The only significant effect of the treat-
ment was found in the dynamic righting reflex. The 
appearence of this reflex was delayed by one day in the 
groups of animals treated via their mothers with 5 and 
50 mg/kg SMe1EC2. However, the delay of this reflex 
was only transient. On day 20 PP all pups tested had a 
positive score of the reflex. We did not consider this subtle 
transient alteration to be due to the adverse effect of the 
substance tested. The delay may be explained by differ-
ent times of delivery. Pups delivered late at night were 
assigned the next day in the morning as their 0 PP day. 
This may have caused the one day shift in the develop-
ment of this reflex. 
The developmental neurotoxicity study based on the 
OECD Guideline No. 426 (2007) recommends to adminis-
ter the chemical substance during pregnancy and lactation 
and to evaluate postnatal development up to adulthood. 
Investigation of somatic growth and maturation, reflex 
and neuromotor development, sensory function, activity 
and emotional reactivity, memory and learning processes 
should be performed within the study. However, recent 
studies showed that other behavioral characteristics, 
such as anxiety, depression, abnormal social behavior or 
altered stress responsiveness can occur due to develop-
mental exposure to various factors during the postnatal 
period (Ferguson et al., 2009; Braquenier et al., 2010.). 
These changes may manifest at late adulthood or even in 
senescence or in reaction to stressful stimuli (Makatsori et 
al., 2005). In our opinion, the battery of tests for chemical 
substances based on the OECD Guideline No. 426 (2007) 
does not involve all behavioral characteristics. Testing of 
social and reproductive behavior, anxiety and/or depres-
sion and reactivity to stressful stimuli should be included 
in this kind of studies. Thus also with the pyridoindole 
SMe1EC2 furher behavioral tests have to be conducted. 
In conclusion, the results of this study showed a rela-
tive safety of SMe1EC2 on postnatal development of rat 
offspring from the point of view of somatic growth and 
maturation, reflex and neuromotor development, as well 
as exploratory behavior in a new environment. 
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